Core Points - The Shanghai Stock Exchange International Investor Conference will be held on November 12-13, focusing on "Value Leading Open Empowerment - New Opportunities for International Capital Investment and Mergers and Acquisitions" [1] - This marks the seventh consecutive year the SSE has hosted the conference, providing a platform for foreign institutions to communicate with domestic regulatory bodies, exchanges, listed companies, and financial institutions [1] Group 1 - The opening remarks will be delivered by leaders from the China Securities Regulatory Commission, Shanghai Municipal Government, and the SSE [1] - Discussions will cover topics such as capital market institutional openness, investment and merger opportunities in the Chinese market, and value investing [1] Group 2 - The first afternoon will feature two sub-forums: one focused on investment, discussing topics like asset allocation in China, ESG, new consumption industry development, exchange-traded funds (ETFs), and the bond market, along with the release of cross-border index investment cooperation results [1] - The second sub-forum will focus on mergers and acquisitions, addressing the development and reform of the Chinese M&A market and cross-border M&A [1] Group 3 - The second day will introduce the latest developments in the Sci-Tech Innovation Board, showcasing the investment value of high-quality Chinese assets [1] - Discussions will center around industries such as artificial intelligence, biomedicine, and high-end equipment manufacturing, featuring industry leaders and representatives from Shanghai-listed companies and domestic and foreign financial institutions [1]

11月11日，必贝特盘中下跌2.01%，截至10:29，报30.65元/股，成交7681.76万元，换手率5.33%，总市 值137.94亿元。 资金流向方面，主力资金净流出679.28万元，大单买入1631.22万元，占比21.24%，卖出2310.51万元， 占比30.08%。 必贝特今年以来股价跌1.16%，近5个交易日跌3.22%。 资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号 A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新 药自主研发。 必贝特所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、抗癌药物、生 物医药、次新股、创新药等。 截至10月28日，必贝特股东户数4.80万，较上期增加95870.00%；人均流通股968股，较上期增加 0.00%。2025年1月-9月，必贝特实现营业收入0.00元；归母净利润-1.07亿元。 责任编辑：小浪快报 今年以来必贝特已经1次登上龙虎榜，最近一次登上龙虎榜为11月5日，当日龙虎榜净买入4188.29万 元；买入总计1.11亿元 ...

Core Points - The Shanghai Stock Exchange International Investor Conference will take place on November 12, focusing on "Value Leading Open Empowerment - New Opportunities for International Capital Investment and Mergers and Acquisitions" [1] - This marks the seventh consecutive year the SSE has hosted this conference, aimed at providing a platform for foreign investment institutions to communicate with domestic regulatory bodies, listed companies, and financial institutions [1] Group 1: Conference Overview - The opening remarks will be delivered by officials from the China Securities Regulatory Commission (CSRC), Shanghai Municipal Government, and the SSE [1] - Key discussions will include topics such as capital market institutional openness, investment and merger opportunities in the Chinese market, and value investing [1] Group 2: Sub-forums - The first sub-forum will focus on investment topics, including asset allocation in China, ESG, new consumption industry development, exchange-traded funds (ETFs), and the bond market, along with the release of cross-border index investment cooperation results [1] - The second sub-forum will address the development and reform of the Chinese merger and acquisition market, as well as cross-border mergers and acquisitions [1] Group 3: Day Two Highlights - The second day will showcase the latest developments in the Sci-Tech Innovation Board, emphasizing the investment value of high-quality Chinese assets [1] - Discussions will revolve around industries such as artificial intelligence, biomedicine, and high-end equipment manufacturing, featuring industry leaders and representatives from Shanghai-listed companies and domestic and foreign financial institutions [1]

Core Viewpoint - The State Council has issued an implementation opinion to accelerate the cultivation and opening of application scenarios, marking a systematic deployment at the national level for the first time [1] Group 1: Definition and Importance of Scenarios - Scenarios are defined as specific contexts for the innovative application of new technologies, products, and business models, serving as a bridge between technology and industry [2] - The cultivation of scenarios is aimed at leveraging China's large market and diverse application scenarios to create experimental fields for new technologies and products, thus accelerating their industrialization [2] Group 2: Multi-Party Efforts in Scenario Cultivation - The Ministry of Industry and Information Technology has supported 46 cities in promoting digital and green technologies, and has implemented insurance compensation policies for major technological equipment [3] - Anhui Province plans to establish nearly 300 application scenarios by the end of this year and aims for 1,000 by 2027, focusing on quantum information [3] Group 3: Role of Central Enterprises - Central enterprises are seen as a rich source for scenario supply, providing over 400 pilot services and collaborating with various entities to enhance technological innovation and industrial renewal [4] Group 4: Future Directions and Mechanisms - The Ministry of Science and Technology will focus on key core technology breakthroughs and the efficient transformation of major technological achievements to drive new industrial momentum [6] - The State-owned Assets Supervision and Administration Commission aims to enhance the supply of high-value scenarios and broaden the scope of scenario opening, encouraging participation from various business entities [6] Group 5: Implementation and Coordination - Effective implementation of the opinion requires strengthening collaboration, highlighting key areas, and improving mechanisms to support the establishment of a diverse scenario cultivation system [7]

Core Insights - The State Council has issued a systematic deployment for scene cultivation and opening, marking a significant step in promoting high-quality development through innovative applications of new technologies and products [1][2] Group 1: Definition and Importance of Scenes - "Scenes" are defined as specific contexts for the innovative application of new technologies, products, and business models, serving as a bridge between technology and industry [2] - The cultivation of scenes is seen as a key resource for innovation, facilitating the transformation of technological achievements into productive forces [2] Group 2: Implementation and Support - The Ministry of Industry and Information Technology has supported 46 cities in promoting smart and green technologies, with plans to establish 63 provincial future industry pilot zones [3] - Various provinces, such as Anhui and Guangdong, are actively developing application scenarios, with Anhui aiming to implement nearly 300 scenarios by the end of the year and 1,000 by 2027 [3][4] Group 3: Role of Central Enterprises - Central enterprises are identified as significant contributors to scene supply, with 190 pilot verification platforms providing over 400 services to various sectors [4] - The State-owned Assets Supervision and Administration Commission is encouraging the participation of private and small enterprises in scene construction [5] Group 4: Future Directions and Coordination - The focus will be on strengthening core technology breakthroughs and enhancing the role of enterprises in technological innovation [5] - The implementation of the opinions will require coordinated efforts to expand market access and explore new market configurations for innovative elements [6]

Core Viewpoint - The stock of Haishike has shown a significant increase of 64.01% year-to-date, despite a recent decline of 2.96% over the past five trading days, indicating volatility in its performance [1][2]. Financial Performance - For the period from January to September 2025, Haishike achieved a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% [2]. - The top ten circulating shareholders include several institutional investors, with notable increases in holdings from entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On November 10, Haishike's stock price rose by 2.04% to 54.09 yuan per share, with a trading volume of 123 million yuan and a turnover rate of 0.48%. The total market capitalization reached 60.576 billion yuan [1]. - The net outflow of main funds was 237,700 yuan, while large orders showed a mixed trend with 9.09 million yuan in purchases and 10.61 million yuan in sales [1]. Business Overview - Haishike Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sales of chemical pharmaceuticals, with its main revenue sources being anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including Helicobacter pylori, hypertension treatment, and innovative drugs [1].

Core Viewpoint - Shenzhou Cell's stock has shown significant volatility, with a year-to-date increase of 40.52%, but recent declines in the short term raise concerns about its performance [1][2]. Company Overview - Shenzhou Cell, established on April 23, 2007, and listed on June 22, 2020, is based in Beijing and focuses on the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune disorders [1]. - The company's main business revenue is derived entirely from product sales [1]. Financial Performance - For the period from January to September 2025, Shenzhou Cell reported a revenue of 1.312 billion yuan, a year-on-year decrease of 32.27%, and a net profit attributable to shareholders of -251 million yuan, reflecting a significant decline of 267.17% [2]. - As of September 30, 2025, the number of shareholders increased by 40.96% to 13,700, while the average circulating shares per person decreased by 29.06% to 32,390 shares [2]. Stock Market Activity - As of November 10, Shenzhou Cell's stock price was 50.91 yuan per share, with a market capitalization of 22.672 billion yuan [1]. - The stock has experienced a net outflow of 4.3243 million yuan in principal funds, with significant buying and selling activity from large orders [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 4, where it saw a net purchase of 87.5322 million yuan [1]. Shareholder Composition - As of September 30, 2025, the sixth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 4.6168 million shares as a new shareholder [2]. - The seventh-largest shareholder is Southern CSI 500 ETF, which reduced its holdings by 93,400 shares [2]. - The tenth-largest shareholder is Innovation Drug, also a new entrant with 1.7893 million shares [2].

Core Viewpoint - Bid Pharma's stock price has shown a significant increase of 50.29% year-to-date, with a current market capitalization of 6.597 billion yuan, indicating strong investor interest and performance in the pharmaceutical sector [1][2]. Financial Performance - For the period from January to September 2025, Bid Pharma achieved a revenue of 979 million yuan, representing a year-on-year growth of 20.67%. The net profit attributable to shareholders was 120 million yuan, reflecting a substantial increase of 42.79% compared to the previous year [2]. - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3]. Stockholder Information - As of September 30, 2025, the number of shareholders for Bid Pharma decreased by 7.64% to 3,493, while the average number of circulating shares per person increased by 8.27% to 12,377 shares [2]. - The top ten circulating shareholders include notable institutional investors, with China Europe Medical Health Mixed A being the second-largest shareholder, increasing its holdings by 20.07% [3]. Market Activity - On November 10, Bid Pharma's stock rose by 2.07%, trading at 72.59 yuan per share with a total transaction volume of 23.1378 million yuan. The stock has experienced a slight decline of 1.71% over the past five trading days but has shown a positive trend over longer periods [1].

Core Viewpoint - Kanghong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 67.32%, but recent declines in the short term indicate potential market concerns [1][2]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical reported a revenue of 3.624 billion yuan, reflecting a year-on-year growth of 6.23%. The net profit attributable to shareholders was 1.033 billion yuan, with a growth of 6.08% compared to the previous year [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.040 billion yuan distributed over the last three years [3]. Stock Market Activity - As of November 10, 2023, Kanghong Pharmaceutical's stock price was 31.79 yuan per share, with a market capitalization of 29.289 billion yuan. The stock experienced a trading volume of 147 million yuan and a turnover rate of 0.68% [1]. - The stock has seen a net outflow of 4.0184 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Structure - As of October 20, 2023, the number of shareholders increased to 24,900, a rise of 3.53%. The average number of circulating shares per shareholder decreased by 3.41% to 27,592 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 28.007 million shares, an increase of 730,000 shares from the previous period [3].

Core Viewpoint - The stock of Jibeier has experienced a decline of 2.02% on November 10, with a current price of 31.01 CNY per share, despite a year-to-date increase of 41.73% [1] Financial Performance - For the period from January to September 2025, Jibeier achieved a revenue of 704 million CNY, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 476 million CNY, with 252 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jibeier is 7,742, an increase of 28.97% from the previous period, while the average circulating shares per person decreased by 22.46% to 25,759 shares [2] - The top ten circulating shareholders include new entrants such as Caitong Advantage Industry Rotation Mixed A and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3] Stock Market Activity - On November 10, Jibeier's trading volume reached 40.387 million CNY, with a turnover rate of 0.65% and a total market capitalization of 6.184 billion CNY [1] - The stock has seen a decline of 9.17% over the last five trading days, 6.60% over the last twenty days, and 1.30% over the last sixty days [1] Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The main revenue sources include Likujun tablets (72.72%), Niqurol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]